{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-025438","form_type":"8-K","ticker":"ETON","cik":"0001710340","company_name":"Eton Pharmaceuticals, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.738779+00:00","generated_at":"2026-05-17T17:53:02.093112+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Eton Q2 product sales $18.9M (+108% YoY); non-GAAP EPS $0.03; raises revenue run-rate guidance","bullets":["Q2 product sales $18.9M, up 108% YoY; GAAP EPS $(0.10), non-GAAP EPS $0.03.","Adjusted EBITDA $3.1M vs ($1.6M) prior year; adjusted gross margin improved to 75%.","Launched KHINDIVI (hydrocortisone oral solution) in June; INCRELEX reached 100 active patients ahead of year-end guidance.","Company projects $80M annual revenue run rate in Q3, one quarter ahead of prior outlook.","ET-600 NDA accepted with PDUFA date Feb 25, 2026; second patent granted."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-025438","json":"https://secwatch.observer/filing/0001437749-25-025438.json","markdown":"https://secwatch.observer/filing/0001437749-25-025438.md","text":"https://secwatch.observer/filing/0001437749-25-025438.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710340/000143774925025438/0001437749-25-025438-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710340/000143774925025438/eton20250802_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:53:02.093112+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}